DOSSIER · 13F-HR · Q2 2026

Logos Global Management LP

$2.3B in tracked AUM across 68 positions as of Q2 2026.

LG
CIK 0001792126 · last filed Jun 30, 2026
Total AUM
$2.3B
as of Q2 2026
Holdings
68
positions
Whale Score
68
68
tracked
Activity
no data
changes this Q
AI Analysis · Q2 2026
Comprehensive Analysis of Logos Global Management LP 13F Filing (Q3 2025)
1. Portfolio Overview

Logos Global Management LP manages a concentrated portfolio valued at approximately $893.24 million as of September 30, 2025. The fund experienced a slight contraction in assets under management (AUM) of 1.2% from the previous quarter ($903.80M), a decline likely driven by a combination of market performance and active capital reallocation rather than net outflows.

The portfolio is char...

2. Key Holdings

The portfolio exhibits a "barbell" structure where a small number of positions command significant capital allocation, while the tail consists of smaller, experimental positions.

  • Top Conviction: The largest holding, REVOLUTION MEDICINES INC (RVMD), represents a massive 14.38% of the total portfolio ($128.43M). This is an exceptionally high concentration for institutional fund management, signaling extreme confidence in the company's prospects. The firm aggressively increased this position by 61.8% during the quarter, adding $65.88M.
  • Core Positions: The next three largest holdings—IDEAYA BIOSCIENCES INC (IDYA) (8.22%), AKERO THERAPEUTICS INC (AKRO) (6.38%), and ARVINAS INC (ARVN) (5.32%)—are all prominent players in the biotechnology space. These top four positions alone account for roughly 34.3% of the entire portfolio's value.
  • Position Sizing: The portfolio weightings drop steadily after the top ten. While the top position is over 14%, positions 20 through 40 range between 2.2% and near zero. This suggests a strategy of backing winners with significant capital while maintaining a "watchlist" of smaller positions.
Analysis generated by 13F Insight from SEC Form 13F filing data · Q2 2026. Methodology

Quarter at a glance — Q2 2026

Position-change comparison pending.

No quarter-over-quarter changes available.

Top 10 holdings

By portfolio weight as of Q2 2026.

#HoldingValueSharesWeight
01
ERAS
ERASCA INC
$223M12.2M9.6%
02
ABVX
ABIVAX SA
$136M1.0M5.9%
03
RVMD
REVOLUTION MEDICINES INC
$131M700K5.6%
04
IDYA
IDEAYA BIOSCIENCES INC
$112M3.0M4.8%
05
BNTX
BIONTECH SE
$94M1.0M4.1%
06
VERA
VERA THERAPEUTICS INC
$94M2.2M4.1%
07
TNGX
TANGO THERAPEUTICS INC
$89M2.9M3.8%
08
PRAX
PRAXIS PRECISION MEDICINES I
$87M260K3.7%
09
CLDX
CELLDEX THERAPEUTICS INC NEW
$78M2.1M3.4%
10
DNTH
DIANTHUS THERAPEUTICS INC
$78M800K3.4%

Filing history

2026Q2Jun 30
$2.3B 16.0%
68 positionsView →
2026Q1Mar 31
$2.0B 21.0%
66 positionsView →
2025Q4Dec 31
$1.7B 85.3%
69 positionsView →
2025Q3Sep 30
$893M 1.2%
43 positionsView →
2025Q2Jun 30
$904M 60.7%
51 positionsLocked
2025Q1Mar 31
$563M 34.2%
39 positionsLocked
2024Q4Dec 31
$855M 7.8%
47 positionsLocked
2024Q3Sep 30
$927M 25.5%
55 positionsLocked
2024Q2Jun 30
$1.2B 0.6%
57 positionsLocked
2024Q1Mar 31
$1.2B 15.3%
57 positionsLocked
2023Q4Dec 31
$1.1B 42.9%
53 positionsLocked
2023Q3Sep 30
$750M 1.9%
56 positionsLocked
Showing 12 of 27